Enliven Therapeutics Inc (ELVN)
17.31
-1.36
(-7.28%)
USD |
NASDAQ |
Apr 17, 16:00
17.31
0.00 (0.00%)
After-Hours: 17:31
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 715.73M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 3.55% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 2.911 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
URL | https://www.enliventherapeutics.com |
Investor Relations URL | https://ir.enliventherapeutics.com/ |
HQ State/Province | Colorado |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | N/A |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 14, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
URL | https://www.enliventherapeutics.com |
Investor Relations URL | https://ir.enliventherapeutics.com/ |
HQ State/Province | Colorado |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | N/A |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 14, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |